mResvia is a messenger RNA vaccine from Moderna indicated for the prevention of RSV respiratory infections in seniors. Not marketed to date, it has just obtained a favorable opinion for its reimbursement.
The High Authority for Health (HAS) has spoken out “favorably reimbursement of the mResvia vaccine (Moderna messenger RNA vaccine) for the prevention of infections due to respiratory syncytial virus (RSV) in subjects aged 75 and over, as well as in subjects aged 65 and over with respiratory pathologies chronic (particularly COPD) or cardiac (particularly heart failure) likely to decompensate during an RSV infection.”
mResvia (from Moderna), which is not yet marketed, is the first messenger RNA vaccine in this indication, the other vaccines being Abrysvo (recombinant bivalent vaccine, from Pfizer) and Arexvy (recombinant vaccine with adjuvant, from GlaxoSmithKline). The latter two are already on the market but are not yet refundable for seniors. They also received a favorable opinion for their reimbursement in this indication in September 2024.
In its opinion of November 21, 2024, HAS considers that “the mResvia vaccine can be used, in the same way as other RSV vaccines, as part of the current vaccination strategy against RSV infections in seniors”, but she “does not comment, at this stage, on the relevance and necessity of iterative vaccination after the primary vaccination”.
The health authority also considers that the mResvia vaccine can be administered concomitantly with the flu and Covid-19 vaccines, at different injection sites. If the vaccines against RSV, influenza and Covid-19 are not administered at the same time, the HAS reminds that there is no time limit to be respected between the three vaccinations and that in general, it is not It is not necessary to respect a minimum time between an RSV vaccine and any other vaccine in the vaccination schedule. However, she specifies that the concomitant administration of mResvia and other vaccines recommended in these age groups has not been studied.
Health
